The RISK of ROCK

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 292, Issue 6, 2007, Pages

  Manintveld, Olivier C ^a   Verdouw, Pieter D ^a   Duncker, Dirk J ^a,b  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; FASUDIL; PROTEIN KINASE; REPERFUSION INJURY SALVAGE KINASE; RHO KINASE; UNCLASSIFIED DRUG;

ANGINA PECTORIS; ATHEROSCLEROSIS; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CORONARY ARTERY DISEASE; CORONARY ARTERY SPASM; DRUG EFFECT; DRUG MECHANISM; DRUG MEGADOSE; EDITORIAL; ENZYME INHIBITION; ERECTILE DYSFUNCTION; EXERCISE TOLERANCE; HEART FAILURE; HEART INFARCTION; HEART INFARCTION SIZE; HEART MUSCLE INJURY; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; ISCHEMIC PRECONDITIONING; KIDNEY ISCHEMIA; LIVER ISCHEMIA; LIVER PROTECTION; MITOCHONDRIAL PERMEABILITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; RENAL PROTECTION; REPERFUSION INJURY; VASCULITIS;

1-(5-ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE; 1-PHOSPHATIDYLINOSITOL 3-KINASE; AMIDES; ANIMALS; APOPTOSIS; CARDIOTONIC AGENTS; CORONARY CIRCULATION; ENZYME ACTIVATION; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-AKT; PYRIDINES; RESEARCH DESIGN; SIGNAL TRANSDUCTION;

EID: 34447558240     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00179.2007     Document Type: Editorial

References (24)

1. Bao W, Hu E, Tao L, Boyce R, Mirabile R, Thudium DT, Ma XL, Willette RN, Yue TL. Inhibition of Rho-kinase protects the heart against ischemia/reperfusion injury. Cardiovasc Res 61: 548-558, 2004.
2. Crisostomo PR, Wairiuko GM, Wang M, Tsai BM, Morrell ED, Meldrum DR. Preconditioning versus postconditioning: mechanisms and therapeutic potentials. J Am Coll Surg 202: 797-812, 2006.
3. Del Re DP, Miyamoto S, Brown JH. RhoA/Rho kinase up-regulate Bax to activate a mitochondrial death pathway and induce cardiomyocyte apoptosis. J Biol Chem 282: 8069-8078, 2007.
4. Demiryurek S, Kara AF, Celik A, Babul A, Tarakcioglu M, Demiryurek AT. Effects of fasudil, a Rho-kinase inhibitor, on myocardial preconditioning in anesthetized rats. Eur J Pharmacol 527: 129-140, 2005.
5. Demiryurek S, Kara AF, Celik A, Tarakcioglu M, Bagci C, Demiryurek AT. Effects of Y-27632, a selective Rho-kinase inhibitor, on myocardial preconditioning in anesthetized rats. Biochem Pharmacol 69: 49-58, 2005.
6. Hamid SA, Bower HS, Baxter GF. Rho kinase activation plays a major role as a mediator of irreversible injury in reperfused myocardium. Am J Physiol Heart Circ Physiol 292: H2598-H2606, 2007.
7. Hausenloy DJ, Tsang A, Yellon DM. The reperfusion injury salvage kinase pathway: a common target for both ischemic preconditioning and postconditioning. Trends Cardiovasc Med 15: 69-75, 2005.
8. Hausenloy DJ, Yellon DM. Survival kinases in ischemic preconditioning and postconditioning. Cardiovasc Res 70: 240-253, 2006.
9. Ikeda F, Terajima H, Shimahara Y, Kondo T, Yamaoka Y. Reduction of hepatic ischemia/reperfusion-induced injury by a specific ROCK/Rho kinase inhibitor Y-27632. J Surg Res 109: 155-160, 2003.
10. Kloner RA, Rezkalla SH. Preconditioning, postconditioning and their application to clinical cardiology. Cardiovasc Res 70: 297-307, 2006.
11. Liem DA, Te Lintel Hekkert M, Manintveld OC, Boomsma F, Verdouw PD, Duncker DJ. Myocardium tolerant to an adenosine-dependent ischemic preconditioning stimulus can still be protected by stimuli that employ alternative signaling pathways. Am J Physiol Heart Circ Physiol 288: H1165-H1172, 2005.
12. 3 receptors. Cardiovasc Res 51: 701-708, 2001.
13. Manintveld OC, Te Lintel Hekkert M, van den Bos EJ, Suurenbroek GM, Dekkers D, Verdouw PD, Lamers JM, Duncker DJ. Cardiac effects of postconditioning depend critically on the duration of index ischemia. Am J Physiol Heart Circ Physiol 292: H1551-H1560, 2007.
14. Nohria A, Grunert ME, Rikitake Y, Noma K, Prsic A, Ganz P, Liao JK, Creager MA. Rho kinase inhibition improves endothelial function in human subjects with coronary artery disease. Circ Res 99: 1426-1432, 2006.
15. Noma K, Oyama N, Liao JK. Physiological role of ROCKs in the cardiovascular system. Am J Physiol Cell Physiol 290: C661-C668, 2006.
16. Riento K, Ridley AJ. Rocks: multifunctional kinases in cell behaviour. Nat Rev Mol Cell Biol 4: 446-456, 2003.
17. Rikitake Y, Kim HH, Huang Z, Seto M, Yano K, Asano T, Moskowitz MA, Liao JK. Inhibition of Rho kinase (ROCK) leads to increased cerebral blood flow and stroke protection. Stroke 36: 2251-2257, 2005.
18. Sanada S, Asanuma H, Tsukamoto O, Minamino T, Node K, Takashima S, Fukushima T, Ogai A, Shinozaki Y, Fujita M, Hirata A, Okuda H, Shimokawa H, Tomoike H, Hori M, Kitakaze M. Protein kinase A as another mediator of ischemic preconditioning independent of protein kinase C. Circulation 110: 51-57, 2004.
19. Shimokawa H. Rho-kinase as a novel therapeutic target in treatment of cardiovascular diseases. J Cardiovasc Pharmacol 39: 319-327, 2002.
20. Shimokawa H, Hiramori K, Iinuma H, Hosoda S, Kishida H, Osada H, Katagiri T, Yamauchi K, Yui Y, Minamino T, Nakashima M, Kato K. Anti-anginal effect of fasudil, a Rho-kinase inhibitor, in patients with stable effort angina: a multicenter study. J Cardiovasc Pharmacol 40: 751-761, 2002.
21. Shimokawa H, Takeshita A. Rho-kinase is an important therapeutic target in cardiovascular medicine. Arterioscler Thromb Vasc Biol 25: 1767-1775, 2005.
22. Teraishi K, Kurata H, Nakajima A, Takaoka M, Matsumura Y. Preventive effect of Y-27632, a selective Rho-kinase inhibitor, on ischemia/reperfusion-induced acute renal failure in rats. Eur J Pharmacol 505: 205-211, 2004.
23. Vicari RM, Chaitman B, Keefe D, Smith WB, Chrysant SG, Tonkon MJ, Bittar N, Weiss RJ, Morales-Ballejo H, Thadani U. Efficacy and safety of fasudil in patients with stable angina: a double-blind, placebo-controlled, phase 2 trial. J Am Coll Cardiol 46: 1803-1811, 2005.
24. Wolfrum S, Dendorfer A, Rikitake Y, Stalker TJ, Gong Y, Scalia R, Dominiak P, Liao JK. Inhibition of Rho-kinase leads to rapid activation of phosphatidylinositol 3-kinase/protein kinase Akt and cardiovascular protection. Arterioscler Thromb Vasc Biol 24: 1842-1847, 2004.